Cancer Research Horizons is the innovation engine of Cancer Research UK, translating cutting-edge cancer research into therapeutics, diagnostics, medical devices, and data-driven/AI solutions. It operates a £15m Seed Fund and provides venture creation support to early-stage oncology start-ups.
44% of their portfolio is in Biotech & Life Sciences. They made 4 investments in the last 12 months. Average disclosed round size is $30.9M (across 8 rounds with reported amounts).
Portfolio
13
Fund Size
—
Top Stage
Seed
Last 12 Mo
4
Team
Alessia Errico
Associate Director, Search and Evaluation, and Entrepreneurial Programmes Lead
Bharath Srinivasan
Senior Principal Scientist (Enzymology)
Jon Clark
Principal Scientist, Therapeutic Translation
Susanne Schroeder
Senior Principal Scientist, Mechanistic Pharmacology
Taran Khanam
Senior Principal Scientist, Therapeutic Translation Lead
Kevin Doyle
Vice President of Medicinal Chemistry and DMPK
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 Infinitopes | Seed | $35.1M | Jan 2026 |
| AALTx Therapeutics | Unknown | — | Jan 2026 |
 Trogenix | Series A | — | Oct 2025 |
 Trogenix | Series A | $70M | Oct 2025 |
 AiM Medical Robotics | Series A | $8.1M | Sep 2025 |
| Trogenix | Series A | $70M | Jan 2025 |
| Infinitopes | Seed | $16M | Apr 2024 |
 NKIO | Seed | — | Jul 2023 |
| AAdendra Therapeutics | Series A | — | Dec 2021 |
 Neobe Therapeutics | Unknown | $2.3M | — |
| 552North | Unknown | — | — |
| AAdaptate Biotherapeutics | Unknown | $18M | — |
| EEnedra | Unknown | $28M | — |
 52North | Growth | — | — |
| LLaigo Bio B.V. | Seed | — | — |
| Trogenix | Seed | — | — |
Top Co-Investors
Last updated: 7 October 2026